| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Xin Yu                                                                                        |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Jiaqi Li                                                                                      |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 th, 2021                                                                                       |
|------------------------------------------------------------------------------------------------------------|
| Your Name:Lingyun Ye                                                                                       |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy                 |
| combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy |
| Manuscript number (if known):                                                                              |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Jing Zhao                                                                                     |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed)                                             | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                                                            | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | This study was supported by the Shanghai Municipal Health Commission (grant number: 20164Y0269). This funding was received by Jing Zhao. | None.                                                                               |
|   |                                                                                                                                                                       | Time frame: past                                                                                                                         | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated                                                                                                                 | XNone                                                                                                                                    |                                                                                     |

| Royalties or licenses  X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     | in item #1 above).         |         |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------|---------|--|
| 5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel  8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advoaccy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 3   | Royalties or licenses      | XNone   |  |
| 5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel  8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advoaccy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |     |                            |         |  |
| 5 Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel  8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advoaccy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | _   |                            |         |  |
| lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4   | Consulting fees            | XNone   |  |
| lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                            |         |  |
| lectures, presentations, speakers bureaus, manuscript writing or educational events  6 Payment for expert testimony  7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | г   | Dayment or heneraria for   | V None  |  |
| speakers bureaus, manuscript writing or educational events 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5   |                            | xnone   |  |
| manuscript writing or educational events  Payment for expert testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Manual Man |     |                            |         |  |
| educational events Payment for expert testimony  Support for attending meetings and/or travel  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Receipt of equipment, materials, drugs, medical writing, gifts or other services  A None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                            |         |  |
| testimony  Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Table Value of the value of th |     |                            |         |  |
| 7 Support for attending meetings and/or travel  8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 6   | Payment for expert         | XNone   |  |
| 8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     | testimony                  |         |  |
| 8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |     |                            |         |  |
| 8 Patents planned, issued or pending  9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 7   |                            | XNone   |  |
| Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Receipt of equipment, materials or non-  Materials, drugs, medical writing, gifts or other services  Materials or non-  M |     | -                          |         |  |
| Participation on a Data Safety Monitoring Board or Advisory Board  Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Receipt of equipment, materials or non-  Materials, drugs, medical writing, gifts or other services  Materials or non-  M |     |                            |         |  |
| 9 Participation on a Data Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 8   | Patents planned, issued or | XNone   |  |
| Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  2 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  A None  A None  A None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |     | pending                    |         |  |
| Safety Monitoring Board or Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  2 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  A None  A None  A None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |     |                            |         |  |
| Advisory Board  10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  2 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  2 Leadership or fiduciary role in X_None  2 X_None  2 X_None  3 Other financial or non-  4 X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 9   | Participation on a Data    | XNone   |  |
| 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-    X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                            |         |  |
| in other board, society, committee or advocacy group, paid or unpaid  11 Stock or stock options XNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                            |         |  |
| committee or advocacy group, paid or unpaid  11 Stock or stock options X_None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonX_None X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10  |                            | XNone   |  |
| group, paid or unpaid  11 Stock or stock options  X_None  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or non-  X_None  X_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |     |                            |         |  |
| 11 Stock or stock options XNone  12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone XNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                            |         |  |
| 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services  13 Other financial or nonX_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 4.4 |                            |         |  |
| materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11  | Stock or stock options     | XNone   |  |
| materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     |                            |         |  |
| materials, drugs, medical writing, gifts or other services  13 Other financial or nonXNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12  | Pacaint of aguinment       | V None  |  |
| writing, gifts or other services  13 Other financial or nonX_None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12  |                            | ^_Notie |  |
| services         13 Other financial or non-        XNone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |     |                            |         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     |                            |         |  |
| financial interests                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13  | Other financial or non-    | XNone   |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     | financial interests        |         |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |     |                            |         |  |

This study was supported by the Shanghai Municipal Health Commission (grant number: 20164Y0269). This funding was received by Jing Zhao.

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Mengqing Xie                                                                                  |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                                                       | 1      |  |
|----|-------------------------------------------------------|--------|--|
|    |                                                       |        |  |
|    |                                                       |        |  |
| 5  | Payment or honoraria for                              | XNone  |  |
|    | lectures, presentations,                              |        |  |
|    | speakers bureaus,                                     |        |  |
|    | manuscript writing or                                 |        |  |
|    | educational events                                    |        |  |
| 6  | Payment for expert                                    | XNone  |  |
|    | testimony                                             |        |  |
|    |                                                       |        |  |
| 7  | Support for attending                                 | XNone  |  |
|    | meetings and/or travel                                |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
| 8  | Patents planned, issued or                            | X None |  |
|    | pending                                               |        |  |
|    | , - · · · ·                                           |        |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or | XNone  |  |
|    |                                                       |        |  |
|    | Advisory Board                                        |        |  |
| 10 | Leadership or fiduciary role                          | XNone  |  |
|    | in other board, society,                              |        |  |
|    | committee or advocacy                                 |        |  |
|    | group, paid or unpaid                                 |        |  |
| 11 | Stock or stock options                                | X None |  |
|    | •                                                     |        |  |
|    |                                                       |        |  |
| 12 | Receipt of equipment,                                 | X_None |  |
|    | materials, drugs, medical                             |        |  |
|    | writing, gifts or other                               |        |  |
|    | services                                              |        |  |
| 13 | Other financial or non-                               | X None |  |
|    | financial interests                                   |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Juan Zhou                                                                                     |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| n EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy            |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                                                       | 1      |  |
|----|-------------------------------------------------------|--------|--|
|    |                                                       |        |  |
|    |                                                       |        |  |
| 5  | Payment or honoraria for                              | XNone  |  |
|    | lectures, presentations,                              |        |  |
|    | speakers bureaus,                                     |        |  |
|    | manuscript writing or                                 |        |  |
|    | educational events                                    |        |  |
| 6  | Payment for expert                                    | XNone  |  |
|    | testimony                                             |        |  |
|    |                                                       |        |  |
| 7  | Support for attending                                 | XNone  |  |
|    | meetings and/or travel                                |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
| 8  | Patents planned, issued or                            | X None |  |
|    | pending                                               |        |  |
|    | , - · · · ·                                           |        |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or | XNone  |  |
|    |                                                       |        |  |
|    | Advisory Board                                        |        |  |
| 10 | Leadership or fiduciary role                          | XNone  |  |
|    | in other board, society,                              |        |  |
|    | committee or advocacy                                 |        |  |
|    | group, paid or unpaid                                 |        |  |
| 11 | Stock or stock options                                | X None |  |
|    | •                                                     |        |  |
|    |                                                       |        |  |
| 12 | Receipt of equipment,                                 | X_None |  |
|    | materials, drugs, medical                             |        |  |
|    | writing, gifts or other                               |        |  |
|    | services                                              |        |  |
| 13 | Other financial or non-                               | X None |  |
|    | financial interests                                   |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |
|    |                                                       |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Yinchen Shen                                                                                  |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Fei Zhou                                                                                      |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |
|                                                                                                         |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | XNone                                                                                        |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Yan Wu                                                                                        |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |
|                                                                                                         |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                              | 1      |  |
|----|------------------------------|--------|--|
|    |                              |        |  |
|    |                              |        |  |
| 5  | Payment or honoraria for     | XNone  |  |
|    | lectures, presentations,     |        |  |
|    | speakers bureaus,            |        |  |
|    | manuscript writing or        |        |  |
|    | educational events           |        |  |
| 6  | Payment for expert           | XNone  |  |
|    | testimony                    |        |  |
|    |                              |        |  |
| 7  | Support for attending        | XNone  |  |
|    | meetings and/or travel       |        |  |
|    |                              |        |  |
|    |                              |        |  |
| 8  | Patents planned, issued or   | X None |  |
|    | pending                      |        |  |
|    | , - · · · ·                  |        |  |
| 9  | Participation on a Data      | XNone  |  |
|    | Safety Monitoring Board or   |        |  |
|    | Advisory Board               |        |  |
| 10 | Leadership or fiduciary role | XNone  |  |
|    | in other board, society,     |        |  |
|    | committee or advocacy        |        |  |
|    | group, paid or unpaid        |        |  |
| 11 | Stock or stock options       | X None |  |
|    | •                            |        |  |
|    |                              |        |  |
| 12 | Receipt of equipment,        | X_None |  |
|    | materials, drugs, medical    |        |  |
|    | writing, gifts or other      |        |  |
|    | services                     |        |  |
| 13 | Other financial or non-      | X None |  |
|    | financial interests          |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |
|    |                              |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Chaonan Han                                                                                   |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| n EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy            |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                                                                             | 1      |  |
|----|-----------------------------------------------------------------------------|--------|--|
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 5  | Payment or honoraria for                                                    | XNone  |  |
|    | lectures, presentations,                                                    |        |  |
|    | speakers bureaus,                                                           |        |  |
|    | manuscript writing or                                                       |        |  |
|    | educational events                                                          |        |  |
| 6  | Payment for expert                                                          | XNone  |  |
|    | testimony                                                                   |        |  |
|    |                                                                             |        |  |
| 7  | Support for attending                                                       | XNone  |  |
|    | meetings and/or travel                                                      |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 8  | Patents planned, issued or                                                  | X None |  |
|    | pending                                                                     |        |  |
|    | , - · · · ·                                                                 |        |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or                       | XNone  |  |
|    |                                                                             |        |  |
|    | Advisory Board                                                              |        |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | XNone  |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    | group, paid or unpaid                                                       |        |  |
| 11 | Stock or stock options                                                      | X None |  |
|    | •                                                                           |        |  |
|    |                                                                             |        |  |
| 12 | Receipt of equipment,                                                       | X_None |  |
|    | materials, drugs, medical                                                   |        |  |
|    | writing, gifts or other                                                     |        |  |
|    | services                                                                    |        |  |
| 13 | Other financial or non-                                                     | X None |  |
|    | financial interests                                                         |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                  |                                 |
|-----------------------------------------------------------------------------------|---------------------------------|
| Your Name:Jialin Qian                                                             |                                 |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus ch         | nemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR | -TKI therapy                    |
| Manuscript number (if known):                                                     |                                 |
| -                                                                                 |                                 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                                                                             | 1      |  |
|----|-----------------------------------------------------------------------------|--------|--|
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 5  | Payment or honoraria for                                                    | XNone  |  |
|    | lectures, presentations,                                                    |        |  |
|    | speakers bureaus,                                                           |        |  |
|    | manuscript writing or                                                       |        |  |
|    | educational events                                                          |        |  |
| 6  | Payment for expert                                                          | XNone  |  |
|    | testimony                                                                   |        |  |
|    |                                                                             |        |  |
| 7  | Support for attending                                                       | XNone  |  |
|    | meetings and/or travel                                                      |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 8  | Patents planned, issued or                                                  | X None |  |
|    | pending                                                                     |        |  |
|    | , - · · · ·                                                                 |        |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or                       | XNone  |  |
|    |                                                                             |        |  |
|    | Advisory Board                                                              |        |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | XNone  |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    | group, paid or unpaid                                                       |        |  |
| 11 | Stock or stock options                                                      | X None |  |
|    | •                                                                           |        |  |
|    |                                                                             |        |  |
| 12 | Receipt of equipment,                                                       | X_None |  |
|    | materials, drugs, medical                                                   |        |  |
|    | writing, gifts or other                                                     |        |  |
|    | services                                                                    |        |  |
| 13 | Other financial or non-                                                     | X None |  |
|    | financial interests                                                         |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Tianqing Chu                                                                                  |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | XNone                                                                                        |                                                                                     |
|   |                                                                                                                                                                       | Time frame: past                                                                             | 36 months                                                                           |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                                                                                              | XNone                                                                                        |                                                                                     |
| 3 | Royalties or licenses                                                                                                                                                 | X_None                                                                                       |                                                                                     |
| 4 | Consulting fees                                                                                                                                                       | XNone                                                                                        |                                                                                     |

| -  |                                                                             | 1      |  |
|----|-----------------------------------------------------------------------------|--------|--|
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 5  | Payment or honoraria for                                                    | XNone  |  |
|    | lectures, presentations,                                                    |        |  |
|    | speakers bureaus,                                                           |        |  |
|    | manuscript writing or                                                       |        |  |
|    | educational events                                                          |        |  |
| 6  | Payment for expert                                                          | XNone  |  |
|    | testimony                                                                   |        |  |
|    |                                                                             |        |  |
| 7  | Support for attending                                                       | XNone  |  |
|    | meetings and/or travel                                                      |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
| 8  | Patents planned, issued or                                                  | X None |  |
|    | pending                                                                     |        |  |
|    | , - · · · ·                                                                 |        |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or                       | XNone  |  |
|    |                                                                             |        |  |
|    | Advisory Board                                                              |        |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy | XNone  |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    | group, paid or unpaid                                                       |        |  |
| 11 | Stock or stock options                                                      | X None |  |
|    | •                                                                           |        |  |
|    |                                                                             |        |  |
| 12 | Receipt of equipment,                                                       | X_None |  |
|    | materials, drugs, medical                                                   |        |  |
|    | writing, gifts or other                                                     |        |  |
|    | services                                                                    |        |  |
| 13 | Other financial or non-                                                     | X None |  |
|    | financial interests                                                         |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |
|    |                                                                             |        |  |

| None. |  |  |  |
|-------|--|--|--|
|       |  |  |  |

Please place an "X" next to the following statement to indicate your agreement:

| Date:Sep. 5 <sup>th</sup> , 2021                                                                        |
|---------------------------------------------------------------------------------------------------------|
| Your Name:Chunxia Su                                                                                    |
| Manuscript Title: Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations |
| in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy           |
| Manuscript number (if known):                                                                           |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                                                                                                                                                                       | Name all entities with whom you have this relationship or indicate none (add rows as needed)                                                                                                                                                                                                                                                                 | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
|   |                                                                                                                                                                       | Time frame: Since the initial                                                                                                                                                                                                                                                                                                                                | planning of the work                                                                |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | This study was supported by the Cancer Research Funding of CSCO-Hausen (grant number: Y-HS2019/2-072), the National Natural Science Foundation of China (grant numbers: 81874036, 82072568), the Science and Technology Commission of Shanghai Municipality (grant number: 19411971100) and the Shanghai Shenkang Hospital Development Center (grant number: | None.                                                                               |

|    |                                              | SHDC12020110). And these fundings were received by Chunxia Su. |           |
|----|----------------------------------------------|----------------------------------------------------------------|-----------|
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
|    |                                              | Time frame: past                                               | 36 months |
| 2  | Grants or contracts from                     | XNone                                                          |           |
|    | any entity (if not indicated                 |                                                                |           |
|    | in item #1 above).                           |                                                                |           |
| 3  | Royalties or licenses                        | XNone                                                          |           |
|    |                                              |                                                                |           |
| 4  | Consulting for a                             | V. Nana                                                        |           |
| 4  | Consulting fees                              | XNone                                                          |           |
|    |                                              |                                                                |           |
| 5  | Payment or honoraria for                     | X None                                                         |           |
| 3  | lectures, presentations,                     | XNone                                                          |           |
|    | speakers bureaus,                            |                                                                |           |
|    | manuscript writing or                        |                                                                |           |
|    | educational events                           |                                                                |           |
| 6  | Payment for expert                           | XNone                                                          |           |
|    | testimony                                    |                                                                |           |
|    |                                              |                                                                |           |
| 7  | Support for attending meetings and/or travel | XNone                                                          |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
| 8  | Patents planned, issued or                   | XNone                                                          |           |
|    | pending                                      |                                                                |           |
| 9  | Participation on a Data                      | XNone                                                          |           |
|    | Safety Monitoring Board or                   |                                                                |           |
|    | Advisory Board                               |                                                                |           |
| 10 | Leadership or fiduciary role                 | XNone                                                          |           |
|    | in other board, society,                     |                                                                |           |
|    | committee or advocacy group, paid or unpaid  |                                                                |           |
| 11 | Stock or stock options                       | XNone                                                          |           |
|    |                                              |                                                                |           |
|    |                                              |                                                                |           |
| 12 | Receipt of equipment,                        | X_None                                                         |           |
|    | materials, drugs, medical                    |                                                                |           |

|    | writing, gifts or other services |       |  |
|----|----------------------------------|-------|--|
| 13 | Other financial or non-          | XNone |  |
|    | financial interests              |       |  |
|    |                                  |       |  |

This study was supported by the Cancer Research Funding of CSCO-Hausen (grant number: Y-HS2019/2-072), the National Natural Science Foundation of China (grant numbers: 81874036, 82072568), the Science and Technology Commission of Shanghai Municipality (grant number: 19411971100) and the Shanghai Shenkang Hospital Development Center (grant number: SHDC12020110). And these fundings were received by Chunxia Su.

Please place an "X" next to the following statement to indicate your agreement: